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Abstract 
Celiac disease (CD) is an autoimmune disorder of the small bowel that occurs in 
genetically predisposed people of all ages, from middle infancy, and is caused by a 
reaction to gliadin, a gluten protein. Some patients are diagnosed with symptoms 
related to the decreased absorption of nutrients or with various symptoms which, 
although statistically linked, have no clear relationship with the malfunctioning bowel. 
Classic symptoms of CD include diarrhea, weight loss, and fatigue; bowel symptoms may 
be limited or even absent. In this article we describe the case of a young woman with CD 
who presents with myointimal proliferation. However multiple cases of vessel 
thrombosis have been reported in patients with CD. Despite the fact that no definitive 
relationship between these diseases could be explained, we think this association must 
be remembered especially in cases of young and tenuous women with these vascular 
abnormalities. 
 
Introduction 
Celiac disease (CD) is an immune-mediated enteropathy caused by permanent gluten 
intolerance. It affects genetically susceptibile subjects, with a higher prevalence in females 
(F/M: 2.5/1). Epidemiological studies have shown that the prevalence of CD ranges 
between 1/100 and 1/150 in both Europe and the USA. The histological hallmarks of CD 
are villous subtotal or total atrophy, crypt hyperplasia and lymphoplasmacellular infiltrate 
in the intestinal lamina propria, with an increased production of IgM, IgG and IgA. 
Moreover, changes in intestinal permeability are related to alterations of tight junctions.  
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The mechanisms on the basis of the gluten-related damage of small intestinal mucosa and 
malabsorption are not clarified yet. The immunological hypothesis is the most credited; it 
is supported by the characteristic histopathologic and serologic alterations, the association 
with specific genetic markers (HLA-DQ2 and HLA-DQ8), the improvement of intestinal 
damage after steroid therapy, and the association of CD with other immune-mediated 
diseases. 
The pathogenetic mechanism is an immunological reaction to peptides of the gliadin 
molecule: their high glutamine and proline content renders them resistant to digestion by 
intestinal enzymes. Because of a dysregulation of the zonulin system that causes the 
opening of tight junctions, gliadin peptides cross the intestinal barrier to the lamina 
propria and are deamidated by tissue transglutaminase. The deamidated gliadin 
subsequently binds to either DQ2 or DQ8 molecules on antigen-presenting cells, causing 
MyD88-dependent release of both zonulin and cytokines. Gliadin peptides are also 
presented to T lymphocytes, initiating an aberrant humoral and cell-mediated immune 
response, ultimately responsible for the autoimmune process resulting in villous injury. 
Regarding the clinical presentation we can have different forms of CD: classical and 
oligosymptomatic CD, dominated by symptoms and sequelae of gastrointestinal 
malabsorption, a positive serologic test and villous atrophy on biopsy; silent CD, referring 
to patients who are asymptomatic but have a positive serologic test and villous atrophy on 
biopsy; latent CD, defined by positive serological tests but not histological changes on 
biopsy; and finally, potential CD, characterized by HLA predisposition without clinical, 
serological or histopathological signs of disease. 
The initial clinical appearance of CD is more severe in childhood than in adulthood. 
The most frequent symptoms are: gastrointestinal symptoms such as diarrhea, abdominal 
pain, flatulence, weight loss, steatorrhea, anorexia and, less frequently, nausea and 
vomiting and, in children, impaired growth, short stature and pubertal delay; in females: 
menarche delay, menstrual irregularities, recurrent abortion, intrauterine fetal growth 
retardation, infertility and early menopause; in males: infertility with altered spermatic 
motility and erectile dysfunction [1]. 
Other extraintestinal manifestations, due to micro- and macronutrient malabsorption, 
immune-mediated or of unknown origin, are the following: (1) hematological: iron and 
folate deficiency anemia, splenic atrophy and thrombocytosis, thromboembolism risk; 
(2) skin: Duhring’s dermatitis herpetiformis, psoriasis, clubbing and onychodystrophy, 
skin hyperpigmentation, alopecia, follicular keratosis, hypertrichosis lanuginosa, 
peripheral edema, cutaneous elasticity reduction; (3) psychiatric/psychological: 
irritability, poor school performance, anxiety, depression; (4) musculoskeletal: osteopenia, 
osteoporosis, fractures, dental enamel hypoplasia, arthritis, myopathy, cramps, tetany; 
(5) neurological: peripheral neuropathy with paresthesia, tremors and fatigue, cerebellar 
ataxia, epilepsy with or without cerebral calcifications, migraine, night blindness and 
hemeralopia, dementia, multifocal leukoencephalopathy, chorea, sensorineural hearing 
loss; (6) laboratory and instrumental abnormalities: hypocalcemia, prolonged PT, 
aspecific ECG alterations, hypertransaminasemia. 
Several CD-associated autoimmune disorders have been described and reported, 
including Hashimoto’s thyroiditis, type 1 diabetes mellitus, autoimmune hepatitis and 
cholangitis, primary biliary cirrhosis, Sjogren syndrome, Addison’s disease, peripheral 
neuropathy, psoriasis, idiopathic dilated cardiomyopathy and autoimmune myocarditis. 
Untreated CD is associated with several complications: splenic hypotrophy or atrophy, 
ulcerative jejunitis, enteropathy-associated T cell lymphoma, increased risk for MALT  
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lymphoma, esophageal and oropharyngeal carcinomas, small bowel adenocarcinoma, 
collagenous colitis and lymphocytic colitis. 
Endoscopic evaluation and small bowel biopsy are the gold standard for CD diagnosis 
and should always be performed if the clinical suspicion for CD is strong. Multiple 
biopsies either from the second portion of the duodenum or the proximal jejunum should 
be obtained because the histological alterations may be focal. Recently, a new endoscopic 
technology with additional magnification has raised high expectations for a substantial 
improvement in endoscopic recognition of villous atrophy. Serologic tests are important 
to identify subjects eligible for biopsy. IgA anti-tissue transglutaminase or endomysial 
antibody have a high sensitivity and specificity (approx. 90%). In patients with selective 
IgA deficiency, who are known to be at high risk for CD, IgG class antibodies (for tissue 
transglutaminase or endomysial antibody) should be determined instead of IgA 
antibodies. Other hematologic, biochemical and imaging abnormalities may lead to the 
suspicion and eventually to the diagnosis of CD, such as the following ones: 
(1) steatorrhea in stool examination; (2) hematologic abnormalities such as the presence 
of Howell-Jolly bodies and target cells in the peripheral smear, reflecting hypersplenism 
associated with CD; (3) anemia, thrombocytopenia, leukopenia, and 
hypoprothrombinemia; (4) decreased levels of serum iron, calcium, folate, vitamin D and 
albuminemia, and abnormal liver enzymes as the aminotransferases; (5) radiographic 
changes associated with CD including dilatation of the small intestine and loss of the 
mucosal folds; (6) computerized bone mineralometry can show diffuse demineralization 
and decreased bone mineral density. 
The treatment of CD patients consists in a lifelong strict adherence to a gluten-free 
diet, sometimes associated with supplemental therapy (iron, calcium, zinc, magnesium, 
various vitamins, especially of the B complex). Some CD patients may require steroid 
therapy to obtain clinical and histological improvement. Immunosuppressive therapy, 
such as azathioprine, may be used to decrease steroid dosage. The prognosis of CD is 
usually favorable since the gluten-free diet determines clinical and histological recovery. 
However, 30% of CD patients do not present clinical and histological improvement after a 
gluten-free diet. This group of patients is considered affected by ‘refractory sprue’. This 
condition is rare and its most common cause is the failure to adhere to a strict gluten-free 
diet. Refractory sprue is associated with uncommon complications of CD, such as 
intestinal ulceration, mesenteric lymph node cavitation, T cell lymphomas, and 
collagenous sprue, with an unfavorable prognosis and splenic atrophy, with a consequent 
increased risk for infections and/or thromboembolic complications. 
Case Report 
A 34-year-old woman came under our observation due to the appearance of intermittent 
claudication, initially displayed by a sense of fatigue when walking. Lately her walking autonomy had 
decreased to about 100 meters. No signs worth noting emerged from the anamnesis: both parents were 
in good health, as was the patient’s 9-year-old daughter. There were no cases of familiar pathologies, 
especially cardiovascular. Her menstrual cycle was regular and the patient had never suffered from 
particular ailments, except for rare cases of diarrhea, meteorism and reported difficulty in ‘gaining 
weight’. On objective examination the patient was found to be in a good general condition, alert and 
well oriented in time and space with normal facies, negligible decubitus and no signs of bilateral 
peripheral edemas, apart from an imposing thinness, despite the fact that the patient claimed she ate a 
balanced diet and did not pay any special attention to her weight. The skin had a normal blood supply 
and was normally hydrated, but the subcutaneous panniculus adiposus appeared underrepresented yet 
normally distributed. The muscular mass was slightly hypotonic and hypotrophic. The superficial 
lymph node system was undamaged. Locoregional objective examination was negative.  
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The results of the hematochemical examinations were normal, as were the virological tests, the 
dysplastic markers and the autoimmune pattern. The culture and parasitological test of the feces was 
negative, as was the Vidal-Wright serodiagnosis. However the test for antiendomysial and 
anti-transglutaminase antibodies was positive at 227 U/ml, in addition to minimum serum traces of 
cryoglobulin. Moreover the antigliadin IgA level was elevated. The thrombophilia evaluation results 
(factor V Leiden, prothrombin 20210 gene mutation, lupus anticoagulant, anticardiolipin antibodies, 
protein C, protein S, and homocysteine) were negative. Following these results, the patient underwent 
an esophagogastroduodenoscopy and an ileoscopy that showed: normal esophagus, hypotonic cardia; 
normal gastric mucosa with the exception of moderate antral hyperemia, patent pylorus; a normal 
duodenal bulb with sub-atrophic villi and, especially in the second duodenal portion, marked villous 
atrophy and flattened folds with a ‘scalloped’ appearance. Histological examination of the duodenal 
biopsies showed: in the gastric antrum chronic phlogistic process with no evidence of Helicobacter 
pylori, with modest activity levels, and in the second duodenal portion chronic phlogistic process with 
marked villous atrophy and discreet activity levels, compatible with CD. An abdominal ultrasound scan 
was practically negative. For the circulatory study the patient underwent a global angio-CT of the 
chest-abdominal-pelvic vessels and the lower limbs that showed normal thoracic aorta without parietal 
thrombotic appositions, such as the epiaortic arterial trunks and the intracranial circulation; the calibre 
of the abdominal aorta, in the suprarenal tract, was at the lowest limit with evidence of mainly 
right-lateral parietal thrombotic apposition and the celiac tripod displayed a significant reduction in 
calibre at the origin with poststenotic dilation; the superior mesenteric artery had a slightly reduced 
calibre at the origin; the renal arteries were normal; aortic parietal thrombotic apposition with a marked 
reduction in the vessel calibre of the inferior mesenteric artery and severe stenosis at the level of the 
carrefour with a residual lumen of 0.3 cm: the stenosis extended to the origin of the common iliac 
arteries. The inferior mesenteric artery was filiform. Parietal atheromasia, in part calcified, with a 
moderate degree of stenosis in the mid-istal tract of the iliac arteries. The internal and external iliacs and 
the common, superficial and deep femorals were of reduced calibre. This diagnosis was also confirmed 
by color Doppler examination. 
On completion of the diagnosis, the patient was put on a gluten-free diet, after positioning multiple 
stents at the level of the inferior mesenteric artery with excellent hemodynamic compensation, return of 
the distal flow and elimination of the claudication. At present the patient’s condition is good and we 
evaluated the regression of myointimal proliferation after the beginning of the gluten-free diet with a 
new angio-CT of the chest-abdominal-pelvic vessels after one year. Six months and one year later the 
patient underwent a new esophagogastroduodenoscopy with ileoscopy that showed, especially in the 
second duodenal portion, reduction of villous atrophy. 
Discussion 
As mentioned in the introduction, CD is caused by a reaction to gliadin, a gluten 
protein found in wheat. Upon exposure to gliadin, the enzyme tissue transglutaminase 
modifies the protein, and the immune system cross-reacts with the bowel tissue, causing 
an inflammatory reaction and leading to flattening of the lining of the small intestine, 
which interferes with the absorption of nutrients [2]. CD appears to be polyfactorial [3]. 
About 20–30% of people without CD have inherited an abnormal HLA-DQ2 allele [4], 
which suggests that additional factors are nedeed for CD to develop. Furthermore, about 
5% of those people who do develop CD do not have the DQ2 gene [3]. 
The proteins in food responsible for the immune reaction in CD are the prolamins. 
These are storage proteins rich in proline and glutamine that dissolve in alcohols and are 
resistant to pepsin and chymotrypsin, the two main digestive proteases in the gut. Gliadin 
in wheat is the best-known member of this family, but other prolamins exist [3]. 
Classic symptoms of CD include diarrhea, weight loss, and fatigue; bowel symptoms 
may be limited or even absent. Abdominal pain and mouth ulcers [5] may be present. The 
symptoms are frequently ascribed to irritable bowel syndrome and are only later 
recognized as CD; a small proportion of patients with symptoms of irritable bowel 
syndrome have underlying CD, and screening may be justified [6].  
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CD leads to an increased risk of both adenocarcinoma and lymphoma of the small 
bowel, which returns to baseline with diet. The changes in the bowel make it less capable 
of absorbing nutrients, minerals and fat-soluble vitamins [7]. CD has been linked with a 
number of conditions such as IgA deficiency [8, 9], dermatitis herpetiformis [10], 
epilepsy, ataxia, myelopathy, peripheral neuropathy and schizophrenia [11, 12], infertility, 
hyposplenism [13], diabetes mellitus type 1 [14], autoimmune thyroiditis [15], primary 
biliary cirrhosis [16] and microscopic colitis [17]. 
Serology test is useful both in diagnosing CD with a sensitivity of about 98% and a 
specificity of over 95%. Several serological blood tests exist for CD, but the most 
commonly used ones detect an antibody of the IgA type against particular antigens in the 
small bowel as gliadin, and against endomysium or tissue transglutaminase. It is 
important that a total serum IgA level is checked in parallel because an IgA deficiency is 
possible [18–20]. However the gold standard in the diagnosis of CD is endoscopy with 
multiple biopsies
 of the duodenum or jejunum [21]. 
Today the only effective treatment is a life-long gluten-free diet [22] and only a tiny 
minority of patients suffer from refractory disease. Multiple cases of intra-abdominal 
venous thrombosis have also been reported in patients with CD [1] in the literature such 
as a case of nonischemic central retinal vein occlusion associated with CD [23] that 
suggests that although patients with an inherited or acquired predisposition to 
thrombosis have a lifelong risk, they only experience clinical thrombosis occasionally, and 
that additional exogenous insults are necessary to precipitate a clinical event; in fact 
thrombotic episodes are likely multifactorial events in patients who have an inherent 
predisposition to thrombosis [24–26]. 
Francis et al. [27] noted that in their patients dehydration due to diarrhea was 
associated with central retinal vein occlusion; prothrombotic predisposition is caused by 
hyperviscosity from the circulating antigliadin antibodies or some other yet unknown 
cause in patients with CD. The literature also describes an association between the 
Budd-Chiari syndrome and CD, as in Northern Africa [28] and in Turkey [29]. Here the 
unexplained hypercoagulable state in CD may affect the hepatic veins, the mesenteric 
veins or the splenoportal axis, causing different syndromes; it is merely a different 
expression of the same abnormality related to different sites. The authors believe that the 
reason for the hypercoagulable state may be hyposplenism, and CD with abdominal 
venous thrombosis may be more frequently found if carefully researched [30]. In fact 
other authors [31] said that the Budd-Chiari syndrome, in its secondary form, refers to 
the syndrome caused by such diseases as myeloproliferative disorders [32–34], including 
polycythemia vera [35], antiphospholipid antibodies [36, 37], paroxysmal nocturnal 
hemoglobinuria [38, 39], systemic lupus erythematosus [40], Behçet disease [41, 42], CD 
[43], hepatocellular carcinoma [44], renal cell carcinoma [45], and those after use of oral 
contraceptives [46, 47] and pregnancy [48, 49]. 
Conclusion 
The present case report suggests an unusual association of myointimal proliferation 
(thrombosis/atheromasia) and CD. Despite the fact that no definitive relationship 
between these diseases could be explained, we think this association must be remembered 
especially in cases of young and tenuous women with these vascular abnormalities. 
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